Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Warner-Lambert

  • News

Executive Summary

Has filed four NDAs since November 1990. Last December, the firm submitted an NDA for Estrostep, a once-daily triphasic oral contraceptive that combines estrogens in a formula designed to reduce side effects and for Accuretic, an antihypertensive that crosses W-L's ace inhibitor Accupril with the diuretic hydrochlorothiazide. On Feb. 14, the company submitted an NDA for pentostatin, an orphan drug for the treatment of hairy cell leukemia. The company's grand slam filing was completed on Feb. 25, with the submission of Lopid SR, a once-daily version of the cholesterol regulator Lopid.

Table

View full table

Tags:
Latest Headlines

Not-For-Profit Models Needed For Commercially Unviable Rare Disease Drugs

EU Urban Wastewater Directive Update ‘Unfairly Targets Pharmaceutical Industry’

Swissmedic Gets New Grant For Regulatory Strengthening In LMICs

Wegovy's Medicare Part D Prospects: Four Million Lives And Counting?

See All
UsernamePublicRestriction

Register

PS019064

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By